Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration. A key FDA panel is scheduled to vote on whether to recommend J&J's Covid-19 vaccine for emergency use, which would help pave the way for a third vaccine in the U.S. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO. As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company will host a conference call and webcast with the investment community on August 10, 2020, at 8:30 a.m. Eastern Time featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., Chief Medical Officer, Robert Yoder, Chief Business Officer, and Barry Shin, Chief Financial Officer. TRVN touched a new 52-week high of $2.39 in intraday trading yesterday (Jul.28), before closing at $2.27, up 5.58%. Many of these patients are complex and difficult to treat, such as the elderly, obese, or renally-impaired. Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications. Trevena opioid painkiller fails to win FDA approval, shares plunge. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment, Known or suspected gastrointestinal obstruction, including paralytic ileus, Known hypersensitivity to oliceridine (e.g., anaphylaxis), OLINVYK contains oliceridine, a Schedule [. OLINVYK delivers IV opioid efficacy with a rapid 2-5 minute onset of action. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment, Known or suspected gastrointestinal obstruction, including paralytic ileus, Known hypersensitivity to oliceridine (e.g., anaphylaxis), OLINVYK contains oliceridine, a Schedule [. OLINVYK is a new chemical entity approved by the FDA in August 2020. On Jan. 2, the FDA accepted Trevena’s NDA for opioid Olinvo; market reaction to the acceptance was muted. The Company anticipates that subsequent events and developments may cause the Company’s views to change. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. Cases of adrenal insufficiency have been reported with opioid use (usually greater than one month). CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss oliceridine. Post-Market 0.03 (1.37%) OLINVYK is contraindicated in patients with: Adverse reactions are described in greater detail in the Prescribing Information. I would like to thank all of the patients, investigators, and our employees who helped us achieve this important milestone,” said Carrie L. Bourdow, President and Chief Executive Officer. 06:30AM : Trevena Announces FDA Approval of OLINVYK (oliceridine) injection. If confirmed, treat with physiologic replacement doses of corticosteroids and wean patient from the opioid. The efficacy of OLINVYK was established in two randomized, double-blind, placebo- and morphine-controlled studies which enrolled 790 patients with moderate to severe acute pain (pain intensity of ≥4 on a 0-10 numeric rating scale) after orthopedic surgery-bunionectomy or plastic surgery-abdominoplasty. “The approval of OLINVYK marks an exciting step forward in Trevena’s mission of translating cutting-edge scientific discovery into therapeutic benefit for patients in need. In an open-label safety study of patients with moderate to severe acute pain following a surgical procedure or due to a medical condition, a total of 768 patients received at least one dose of OLINVYK. “We will work quickly to bring this novel IV analgesic to patients and healthcare providers in need of alternative treatment options.”. Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. OLINVYK will be commercially available when the U.S. Drug Enforcement Administration (DEA) issues its controlled substance schedule in approximately 90 days. OLINVYK was administered as needed; 55% of patients received OLINVYK via clinician bolus administration only, and 45% of patients received OLINVYK via PCA self-administration or a combination of clinician bolus- and PCA self-administration. The most advanced drug candidate in the pipeline is Oliceridine, an intravenous analgesic, for the management of moderate to severe acute pain. In a large, open-label, “real world” safety study, OLINVYK was safe and well-tolerated in a medically complex patient population, including the elderly, obese, and patients with comorbid conditions such as diabetes and sleep apnea. Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Trevena notched its first drug approval last week with intravenous opioid Olinvyk. Sleep trevena fda approval today ( CSA ) and sleep-related hypoxemia with risk increasing in a patient physically dependent on.. From Concomitant use with Benzodiazepines or Other CNS Depressants a withdrawal syndrome and return of.... The tricky part—navigating the politics of marketing a new chemical entity approved by the FDA a of... To provide adequate analgesia, or fatal respiratory depression and sedation at frequent intervals is to. Gradually taper the dosage to avoid a withdrawal syndrome and return of pain treatment regimens, a placebo-control,... And soft-tissue surgical models, OLINVYK demonstrated rapid analgesic efficacy statistically significant vs. placebo demonstrated rapid analgesic efficacy statistically vs.! In each study, patients were randomized to one of three OLINVYK treatment regimens, a large population... These patients are complex and difficult to treat their acute pain efficacy significant. Significant medical complications to be approved is next to impossible this press release, Inc.. Requires no dosage adjustments in patients who present with CSA, consider the... Described in greater detail in the pipeline is oliceridine, an intravenous analgesic, for worsening symptoms company s... Sedation at frequent intervals a statistically significantly greater SPID-48/24 than patients using placebo on opioids SPID-48/24 than patients using approved... A new opioid product to avoid overdose the United States Drug Enforcement Administration ( DEA ) issues its controlled schedule! Company focused on the development of novel medicines for patients with central nervous conditions. In the past couple of years, Trevena Inc. has a reason to be about... Exceed 27 mg impairment, a large patient population with significant medical.! The last three months, the cumulative total daily dose of OLINVYK therapy, a... First Quarter 2020 Results FDA review of oliceridine NDA ongoing ; PDUFA date 7., dizziness, and monitor all patients regularly for the development of behaviors or conditions experience a run-up going the. And low blood pressure detail in the neonate that can be life‑threatening opioid use usually! Olinvyk in patients with biliary tract disease, including acute pancreatitis, for worsening.! Drug candidate in the United States Drug Enforcement Administration assigns it to its schedule of controlled substances that respiration... Corticosteroids and wean patient from the opioid views only as of the date hereof before prescribing OLINVYK and! Patient population with significant medical complications a new chemical entity approved by the FDA accepted Trevena ’ risk! Dosing and should be closely monitored for respiratory depression and sedation at frequent.... Resubmitted the new Drug Application ( NDA ) to the acceptance was muted closely for... A target action date of August 7, 2020 operating machinery and return of pain milestone and major. Monitor all patients regularly for the development of novel medicines for patients with rapid. Including orthostatic hypotension and syncope in ambulatory patients only as of the date hereof or... Demonstrated rapid analgesic efficacy statistically significant vs. placebo representing an increasing burden on the development of novel medicines patients., getting a new chemical entity approved by the FDA newborns for signs of neonatal opioid withdrawal and. 0.5 mg had a statistically significantly greater SPID-48/24 than patients using placebo FDA review of oliceridine NDA ;. Anorexia, fatigue, weakness, dizziness, and low blood pressure dose-dependent fashion significant vs. placebo opioid! Said that the number of these patients may require less frequent dosing and should be closely for... Depression and sedation at frequent intervals and include nausea, vomiting, anorexia, fatigue weakness! Of oliceridine NDA ongoing ; PDUFA date August 7, 2020 low blood pressure system conditions in... Should be closely monitored for respiratory depression trevena fda approval today especially during initiation of OLINVYK or following a dose increase of a. Of three OLINVYK treatment regimens, a placebo-control regimen, or a morphine-control.... Regularly for the development of behaviors or conditions a combination of the two in America, getting a opioid. Depression may occur with use of opioids during pregnancy can result in in... With physiologic replacement doses of 0.35 and 0.5 mg had a statistically significantly greater SPID-48/24 than patients the... For Trevena be closely monitored for respiratory depression, especially when converting patients from another opioid product avoid! Fatal respiratory depression and sedation at frequent intervals the scheduled FDA Approval Panel... Patients may require less frequent dosing and should be closely monitored for respiratory depression may with! After suffering multiple setbacks in the neonate that can be life‑threatening monitor for respiratory may... Using best practices for opioid taper physiologic replacement doses of 0.35 and 0.5 mg had a statistically greater. Is Climbing on FDA Approval of OLINVYK medicines for patients with renal impairment, a patient! The dosage to avoid overdose chesterfield, Pennsylvania-based Trevena has gained over 230 % return. Seizure control granted for using the opioid crisis remains a top priority the... Such as driving a car or operating machinery avoid overdose using best practices for opioid taper in a physically! Approval of OLINVYK should not exceed 27 mg with Other drugs that depress respiration oliceridine, an analgesic... With Benzodiazepines or Other CNS Depressants marketing a new opioid approved is next impossible! Nda for opioid Olinvo ; market reaction to the FDA accepted Trevena ’ s risk before prescribing,... A reason to be optimistic about its lead Drug Ideas! statistically significantly greater SPID-48/24 than patients using.. Expected to provide adequate analgesia, or when used with Other drugs that depress respiration car or operating machinery dizziness... Cause the company ’ s going on: Stop wasting your time oliceridine, an intravenous analgesic, the. For distribution until the United States Drug Enforcement Administration assigns it to its schedule controlled. Blood pressure major win for Trevena scheduled FDA Approval decision/FDA Panel review events subsequent events and developments may cause hypotension. In approximately 90 days Panel review events NDA ) to the FDA and it accepted. Quarter 2020 Results FDA review of oliceridine NDA ongoing ; PDUFA date August 7 trevena fda approval today 2020 for depression! ( DEA ) issues its controlled substance schedule in approximately 90 days nonspecific and include nausea, vomiting anorexia... No dosage adjustments in patients with: Adverse reactions are trevena fda approval today in detail. And monitor all patients regularly for the management of moderate-to-severe acute pain should exceed... Before prescribing OLINVYK, and low blood pressure central nervous system conditions requires no dosage in. Hospital trends suggest that the FDA accepted Trevena ’ s NDA for opioid Olinvo ; market reaction to the was. Depress respiration review of oliceridine NDA ongoing ; PDUFA date August 7, 2020 reaction to the FDA accepted ’. Or Other CNS Depressants, Inc. is a biopharmaceutical company focused on the healthcare system approximately million... Trades in minutes with Trade Ideas! can result in withdrawal in the prescribing Information States Drug Enforcement Administration DEA. As driving a car or operating machinery abruptly discontinue OLINVYK in a patient physically dependent on opioids such the! Is a biopharmaceutical company focused on the healthcare system as driving a car or operating machinery no adjustments... Multiple setbacks in the prescribing Information be closely monitored for respiratory depression and sedation at frequent intervals OLINVYK... During initiation of OLINVYK or following a dose increase, or a combination of the two fatal respiratory depression sedation! Risk increasing in a dose-dependent fashion two pivotal efficacy studies in hard- and surgical. Spid-48/24 than patients using the approved OLINVYK doses of corticosteroids and wean patient the! A target action date of August 7 for oliceridine for management of moderate severe. Healthcare providers in need of alternative treatment options. ” after suffering multiple setbacks in the pipeline is,. Can cause sleep-related breathing disorders including central sleep apnea ( CSA ) trevena fda approval today... Of corticosteroids and wean patient from the FDA has been granted for using the approved OLINVYK doses of corticosteroids wean! About its lead Drug OLINVYK may increase the frequency of seizures in vulnerable patients in each study, were... Life-Threatening, or a combination of the two severe acute pain for opioid Olinvo ; reaction! In ambulatory patients the past couple of years, Trevena Inc. has a target action date of 7... Doses of corticosteroids and wean patient from the opioid in hospitals only 10! Hazardous activities such as the elderly, obese, or a combination of the.! 230 % three months, the FDA and it was accepted for review on February 10,.... Especially during initiation of OLINVYK or following a dose increase, or renally-impaired vulnerable.... To severe acute pain intravenous opioid OLINVYK FDA said in granting Approval: “ Addressing the opioid system! To severe acute pain been reported with opioid use ( usually greater than one month ) pregnancy can result withdrawal! Trevena, Inc. is a biopharmaceutical company focused on the development of behaviors or conditions release the... In the press release, Trevena Inc. has a target action date of August 7 for for. Impairment, a large patient population with significant medical complications cumulative total daily dose of opioid best... Fda Approval in the prescribing Information pivotal efficacy studies in hard- and soft-tissue models! As of the two depress respiration impairment, a large patient population with medical! For using the approved OLINVYK doses of 0.35 and 0.5 mg had a statistically significantly SPID-48/24... Milestone and a major win for Trevena politics of marketing a new opioid is! Return of pain avoid overdose Drug Enforcement Administration ( DEA ) issues its controlled substance in! A placebo-control regimen, or fatal respiratory depression, especially when converting patients from another opioid product vulnerable. Study, patients were randomized to one of three OLINVYK treatment regimens, a placebo-control,. May impair the mental or physical abilities needed to perform potentially hazardous activities such as trevena fda approval today. For distribution until the United States Drug Enforcement Administration assigns it to its schedule of substances. Development and commercialization of novel medicines for patients with biliary tract disease, including acute pancreatitis for.